[Molecular targeted therapy in colorectal cancer and its resistance]
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
Abstract:
The prognosis of advanced colorectal cancer has been improved by introduction of molecular targeting agents, such as bevacizumab and cetuximab. Several clinical trials revealed a median survival time of more than 2 years. However, the main purpose of chemotherapy for advanced colorectal cancer has not been cure but prolongation of life to date. One explanation of the difficulty of cure is the inherent and/or acquired resistance to chemotherapeutic agents and molecular targeting agents. A better understanding of the mechanisms of inherent resistance will make it possible to identify predictive markers of responder or non-responder to select the optimal patients for a certain drug. Additionally, knowledge of the acquired mechanism will provide for the rational development of therapies that circumvent or overcome resistance. Although the mechanisms of the resistance of molecular targeting agents for colorectal cancer are still unclear, the inherent resistance to cetuximab or panitumumab by why of expression of KRAS mutation is the first breakthrough in this field. Further basic research and biomarker analysis of large clinical study are necessary to clarify the resistance to molecular targeting agents.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
